Charles M. Perou
#89,877
Most Influential Person Now
Researcher
Charles M. Perou's AcademicInfluence.com Rankings
Charles M. Peroubiology Degrees
Biology
#4060
World Rank
#6112
Historical Rank
Computational Biology
#50
World Rank
#50
Historical Rank
Genetics
#313
World Rank
#368
Historical Rank
Download Badge
Biology
Charles M. Perou's Degrees
- PhD Genetics Stanford University
- Bachelors Biology University of California, San Diego
Similar Degrees You Can Earn
Why Is Charles M. Perou Influential?
(Suggest an Edit or Addition)Charles M. Perou's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Molecular portraits of human breast tumours (2000) (14829)
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications (2001) (10949)
- Comprehensive molecular portraits of human breast tumors (2012) (7791)
- Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
- Comprehensive molecular characterization of human colon and rectal cancer (2012) (6141)
- Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. (2010) (5816)
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways (2008) (5775)
- Repeated observation of breast tumor subtypes in independent gene expression data sets (2003) (5412)
- Comprehensive molecular profiling of lung adenocarcinoma (2014) (4095)
- Supervised risk predictor of breast cancer based on intrinsic subtypes. (2009) (3801)
- Integrated genomic characterization of endometrial carcinoma (2013) (3708)
- The Somatic Genomic Landscape of Glioblastoma (2013) (3693)
- Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. (2006) (3693)
- Comprehensive genomic characterization of squamous cell lung cancers (2012) (2998)
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (2014) (2895)
- Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013) (2859)
- The Immune Landscape of Cancer (2018) (2766)
- Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (2004) (2618)
- Systematic variation in gene expression patterns in human cancer cell lines (2000) (2228)
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. (2015) (2211)
- Genomic Classification of Cutaneous Melanoma (2015) (2143)
- Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010) (2121)
- The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer (2009) (2033)
- Integrated Genomic Characterization of Papillary Thyroid Carcinoma (2014) (2007)
- Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer (2010) (1978)
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (2007) (1950)
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy (2005) (1851)
- Comprehensive molecular characterization of urothelial bladder carcinoma (2014) (1748)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Identification of genes periodically expressed in the human cell cycle and their expression in tumors. (2002) (1529)
- Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma (2017) (1514)
- Genome-wide analysis of DNA copy-number changes using cDNA microarrays (1999) (1510)
- Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. (1999) (1478)
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma (2016) (1474)
- The molecular portraits of breast tumors are conserved across microarray platforms (2006) (1436)
- Concordance among gene-expression-based predictors for breast cancer. (2006) (1370)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features (2009) (1352)
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer (2015) (1332)
- Diversity of gene expression in adenocarcinoma of the lung (2001) (1320)
- Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2007) (1247)
- Deconstructing the molecular portraits of breast cancer (2010) (1233)
- Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors (2002) (1200)
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin (2014) (1192)
- Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype (2008) (1175)
- Proteogenomics connects somatic mutations to signaling in breast cancer (2016) (1174)
- Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft (2010) (1171)
- MapSplice: Accurate mapping of RNA-seq reads for splice junction discovery (2010) (1150)
- Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. (2017) (1092)
- Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma (2006) (1061)
- Allele-specific copy number analysis of tumors (2010) (934)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (2009) (829)
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas (2016) (826)
- Integrated genomic and molecular characterization of cervical cancer (2017) (762)
- A custom microarray platform for analysis of microRNA gene expression (2004) (734)
- Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015) (726)
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer (2012) (668)
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer (2010) (668)
- Epidemiology of basal-like breast cancer (2008) (663)
- Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays (1999) (601)
- Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. (2002) (591)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (587)
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
- Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (2013) (543)
- Common markers of proliferation (2006) (525)
- Molecular stratification of triple-negative breast cancers. (2010) (522)
- Evaluating the comparability of gene expression in blood and brain (2006) (518)
- Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. (2009) (511)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. (2013) (498)
- Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. (2013) (490)
- Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. (2007) (472)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Adjustment of systematic microarray data biases (2004) (434)
- Triple-Negative Breast Cancer: Risk Factors to Potential Targets (2008) (430)
- TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. (2012) (430)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) (423)
- The Genome Architecture of the Collaborative Cross Mouse Genetic Reference Population (2012) (416)
- Standardizing global gene expression analysis between laboratories and across platforms (2005) (410)
- A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. (2009) (404)
- Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study (2010) (377)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. (2013) (374)
- Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. (2005) (367)
- Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. (2009) (366)
- Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. (2009) (364)
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak (2010) (362)
- MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. (2016) (354)
- Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. (2006) (348)
- Development and verification of the PAM50-based Prosigna breast cancer gene signature assay (2015) (318)
- Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) (2011) (318)
- Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. (2012) (317)
- Asparagine bioavailability governs metastasis in a model of breast cancer (2018) (316)
- A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis (2015) (313)
- Towards a novel classification of human malignancies based on gene expression patterns (2001) (311)
- A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer (2011) (306)
- Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution (2008) (301)
- Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. (2016) (301)
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers (2012) (286)
- AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. (2005) (282)
- Mutation of GATA3 in human breast tumors (2004) (279)
- EGFR associated expression profiles vary with breast tumor subtype (2007) (273)
- Molecular portraits and the family tree of cancer (2002) (272)
- Practical implications of gene-expression-based assays for breast oncologists (2012) (267)
- Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. (2006) (267)
- A Genome-Wide Screen for Promoter Methylation in Lung Cancer Identifies Novel Methylation Markers for Multiple Malignancies (2006) (260)
- Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set (2016) (260)
- The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas (2008) (254)
- Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling (2014) (254)
- Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types (2010) (248)
- FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival (2007) (248)
- Epidemiology of basal-like breast cancer (2008) (240)
- Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. (2016) (235)
- Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. (2012) (235)
- Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression (2004) (232)
- MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 (2013) (226)
- B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer (2019) (224)
- A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen (2012) (223)
- Identification of a basal-like subtype of breast ductal carcinoma in situ. (2007) (221)
- A single-cell and spatially resolved atlas of human breast cancers (2021) (220)
- Merging two gene-expression studies via cross-platform normalization (2008) (218)
- Defining the cellular precursors to human breast cancer (2011) (214)
- A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma (2010) (214)
- Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer (2017) (213)
- An integrated genomics approach identifies drivers of proliferation in luminal subtype human breast cancer (2014) (213)
- How many etiological subtypes of breast cancer: two, three, four, or more? (2014) (213)
- Mammary development meets cancer genomics (2009) (212)
- Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay (2006) (212)
- Systems biology and genomics of breast cancer. (2011) (211)
- TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab (2012) (210)
- Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation (2012) (209)
- Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse (2011) (203)
- Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer (2008) (202)
- The genomic landscape of breast cancer as a therapeutic roadmap. (2013) (201)
- Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? (2011) (201)
- PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. (2009) (200)
- Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer (2014) (198)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells (2011) (195)
- Statistical modeling for selecting housekeeper genes (2004) (193)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer (2014) (181)
- A compact VEGF signature associated with distant metastases and poor outcomes (2009) (179)
- Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas (2017) (178)
- TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer (2008) (176)
- Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes (2011) (175)
- Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer (2004) (174)
- Universal Reference RNA as a standard for microarray experiments (2004) (169)
- Tumor mutational burden is a determinant of immune-mediated survival in breast cancer (2018) (168)
- Gene expression patterns associated with p53 status in breast cancer (2006) (164)
- RNA expression analysis of formalin-fixed paraffin-embedded tumors (2007) (163)
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies (2013) (163)
- RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* (2001) (163)
- Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling (2011) (162)
- Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype (2018) (161)
- Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts (2013) (159)
- Finding large average submatrices in high dimensional data (2009) (157)
- Characterization of mammary tumors from Brg1 heterozygous mice (2008) (154)
- Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. (2010) (154)
- Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures (2011) (153)
- Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. (2017) (148)
- A Comparison of Gene Expression Signatures from Breast Tumors and Breast Tissue Derived Cell Lines (2002) (147)
- PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer (2012) (146)
- ABRA: improved coding indel detection via assembly-based realignment (2014) (144)
- Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. (2015) (141)
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial (2012) (141)
- A Core MYC Gene Expression Signature Is Prominent in Basal-Like Breast Cancer but Only Partially Overlaps the Core Serum Response (2009) (137)
- Defining breast cancer intrinsic subtypes by quantitative receptor expression. (2015) (136)
- ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. (2007) (136)
- Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer (2006) (136)
- The Somatic Genomic Landscape of Glioblastoma (2014) (135)
- Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. (2020) (134)
- Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models (2012) (132)
- The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases (2011) (132)
- Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer (2014) (130)
- A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. (2016) (127)
- Activation of Host Wound Responses in Breast Cancer Microenvironment (2009) (126)
- Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape (2017) (122)
- LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. (2012) (120)
- Integrated study of copy number states and genotype calls using high-density SNP arrays (2009) (118)
- Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. (2014) (117)
- Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. (2013) (117)
- Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. (2017) (115)
- Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy (2015) (115)
- The molecular diversity of Luminal A breast tumors (2013) (114)
- Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer (2013) (114)
- Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival (2011) (114)
- Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer (2018) (111)
- Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma (2012) (110)
- Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. (2017) (110)
- Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. (2012) (109)
- Molecular characterization of human breast tumor vascular cells. (2008) (109)
- Proteogenomic integration reveals therapeutic targets in breast cancer xenografts (2017) (108)
- Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential (2015) (106)
- SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references (2019) (104)
- Clinical implementation of the intrinsic subtypes of breast cancer. (2010) (103)
- MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. (2011) (102)
- VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma (2018) (102)
- Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts (2016) (102)
- Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. (2009) (100)
- Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. (2010) (100)
- Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. (2015) (99)
- Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (99)
- MYC Is Amplified in BRCA1-Associated Breast Cancers (2004) (99)
- Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch (2011) (98)
- Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development (2018) (97)
- Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen (2012) (97)
- Interactions with Fibroblasts Are Distinct in Basal-Like and Luminal Breast Cancers (2010) (96)
- RB1 and p53 at the crossroad of EMT and triple-negative breast cancer (2011) (96)
- c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer (2014) (95)
- Predicting response and survival in chemotherapy-treated triple-negative breast cancer (2014) (94)
- Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study (2018) (93)
- Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases (2016) (92)
- An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer* (2015) (92)
- Molecular stratification of triple-negative breast cancers. (2011) (91)
- CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. (2009) (90)
- MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion (2012) (89)
- Impact of Tumor Microenvironment and Epithelial Phenotypes on Metabolism in Breast Cancer (2012) (88)
- Erratum: Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles (Cell Reports (2017) 18(11) (2780–2794) (S2211124717302140) (10.1016/j.celrep.2017.02.033)) (2017) (88)
- PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer (2013) (88)
- Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. (2016) (87)
- Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance) (2016) (86)
- Cell-State Transitions Regulated by SLUG Are Critical for Tissue Regeneration and Tumor Initiation (2014) (84)
- The molecular basis of breast cancer pathological phenotypes (2017) (82)
- Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. (2018) (80)
- Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer (2013) (80)
- Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. (2013) (79)
- Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models (2014) (77)
- Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. (2015) (77)
- An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2009) (76)
- Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. (2017) (75)
- Integrated RNA and DNA sequencing improves mutation detection in low purity tumors (2014) (75)
- Gene Expression Profile Signatures Indicate a Role for Wnt Signaling in Endothelial Commitment From Embryonic Stem Cells (2006) (74)
- PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) (2016) (73)
- DNA microarrays in breast cancer: the promise of personalised medicine (2003) (73)
- Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. (2012) (72)
- Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. (2018) (71)
- Dietary Energy Balance Modulates Epithelial-to-Mesenchymal Transition and Tumor Progression in Murine Claudin-Low and Basal-like Mammary Tumor Models (2012) (71)
- Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification (2018) (70)
- Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. (2007) (70)
- Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel (2018) (69)
- Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer (2011) (68)
- Development of an immuno tandem mass spectrometry (iMALDI) assay for EGFR diagnosis (2007) (65)
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. (2020) (65)
- Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival (2014) (65)
- Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice (2013) (64)
- Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) as a Breast Cancer Driver (2012) (64)
- A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard (2013) (63)
- Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2013) (63)
- Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. (2015) (62)
- Common genetic variation in TP53 and its flanking genes, WDR79 and ATP1B2, and susceptibility to breast cancer (2007) (62)
- The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium (2011) (62)
- GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network (2018) (62)
- Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. (2011) (62)
- Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. (2014) (61)
- BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. (2014) (60)
- Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer (2018) (58)
- Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-Activating Proteins in Basal-like Breast Cancers. (2016) (55)
- TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases (2014) (55)
- Microscaled proteogenomic methods for precision oncology (2019) (55)
- Vimentin DNA methylation predicts survival in breast cancer (2012) (54)
- Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. (2010) (54)
- Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident (2021) (54)
- Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. (2011) (54)
- High‐throughput amplicon scanning of the TP53 gene in breast cancer using high‐resolution fluorescent melting curve analyses and automatic mutation calling (2008) (53)
- The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy (2019) (53)
- SWI/SNF Chromatin-Remodeling Factor Smarcd3/Baf60c Controls Epithelial-Mesenchymal Transition by Inducing Wnt5a Signaling (2013) (52)
- Performance of Three-Biomarker Immunohistochemistry for Intrinsic Breast Cancer Subtyping in the AMBER Consortium (2015) (51)
- ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. (2013) (51)
- Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis (2013) (51)
- Race-associated biological differences among Luminal A breast tumors (2015) (50)
- Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness (2017) (49)
- Erratum: The somatic genomic landscape of glioblastoma (Cell (2013) 155 (462-477)) (2014) (49)
- Association between breast cancer subtypes and response to neoadjuvant anastrozole (2011) (48)
- Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer (2018) (48)
- Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. (2020) (48)
- Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V’DJer (2016) (48)
- A framework for transcriptome-wide association studies in breast cancer in diverse study populations (2019) (47)
- Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status (2014) (47)
- The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p (2015) (47)
- Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study (2016) (46)
- Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells (2017) (45)
- ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer (2021) (45)
- Microarrays in primary breast cancer--lessons from chemotherapy studies. (2001) (45)
- The association between copy number aberration, DNA methylation and gene expression in tumor samples (2018) (43)
- Multiple Instance Learning for Heterogeneous Images: Training a CNN for Histopathology (2018) (43)
- A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling (2008) (43)
- Invasive Breast Carcinoma: Introduction and general features (2012) (42)
- Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer (2017) (42)
- Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) (2012) (42)
- Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer (2010) (41)
- Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features (2011) (41)
- Sex differences in oncogenic mutational processes (2019) (41)
- High reproducibility using sodium hydroxide-stripped long oligonucleotide DNA microarrays. (2005) (40)
- Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer (2013) (39)
- The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours (2019) (39)
- Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue respository of the Surveillance, Epidemiology, and End Results (SEER) program (2008) (38)
- Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast (2018) (38)
- Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer (2015) (38)
- Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures (2014) (38)
- Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts (2017) (37)
- A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. (2020) (37)
- Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. (2014) (36)
- Prediction of Toxicant-Specific Gene Expression Signatures after Chemotherapeutic Treatment of Breast Cell Lines (2004) (36)
- Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression (2017) (36)
- αB-crystallin expression in breast cancer is associated with brain metastasis (2015) (36)
- Improved indel detection in DNA and RNA via realignment with ABRA2 (2019) (36)
- Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1 (2008) (35)
- Cytokeratin profiles of male breast cancers (2006) (35)
- DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas (2016) (35)
- Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2020) (35)
- Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers (2017) (35)
- Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. (2015) (35)
- DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer (2018) (35)
- Separation of breast cancer and organ microenvironment transcriptomes in metastases (2019) (35)
- Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential (2015) (34)
- CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). (2019) (34)
- Mutation of GATA 3 in human breast tumors (2004) (33)
- Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study (2017) (32)
- Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer (2017) (32)
- Somatic sequence alterations in twenty-one genes selected by expression profile analysis of breast carcinomas (2007) (31)
- Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy (2015) (31)
- Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer* (2015) (31)
- Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns (2013) (31)
- Proper Use of Allele-Specific Expression Improves Statistical Power for cis-eQTL Mapping with RNA-Seq Data (2015) (31)
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). (2009) (30)
- Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches (2020) (29)
- Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series (2019) (29)
- Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo (2012) (29)
- Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. (2009) (29)
- Topological Descriptors of Histology Images (2014) (29)
- Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). (2014) (28)
- BlackOPs: increasing confidence in variant detection through mappability filtering (2013) (28)
- Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. (2013) (28)
- Frequency of breast cancer subtypes among African American women in the AMBER consortium (2018) (28)
- Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. (2015) (27)
- Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro (2013) (27)
- High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype (2016) (27)
- Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule (2017) (27)
- SWISS MADE: Standardized WithIn Class Sum of Squares to Evaluate Methodologies and Dataset Elements (2010) (27)
- CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer (2022) (26)
- Identification of mRNA isoform switching in breast cancer (2016) (26)
- BreakTrans: uncovering the genomic architecture of gene fusions (2013) (26)
- A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse (2016) (26)
- FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. (2020) (25)
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). (2009) (25)
- Intrinsic Subtype and Therapeutic Response Among HER2‐Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial (2017) (25)
- Multiclass Distance-Weighted Discrimination (2013) (25)
- CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer (2015) (25)
- Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). (2004) (25)
- Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. (2012) (24)
- SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples (2014) (24)
- siRNA: a potential tool for future breast cancer therapy? (2006) (24)
- Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes (2016) (24)
- Murine Microenvironment Metaprofiles Associate with Human Cancer Etiology and Intrinsic Subtypes (2013) (24)
- Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. (2021) (23)
- FOXA1 overexpression suppresses interferon signaling and immune response in cancer. (2021) (23)
- Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. (2010) (23)
- Common Genetic Variation in GATA-Binding Protein 3 and Differential Susceptibility to Breast Cancer by Estrogen Receptor α Tumor Status (2007) (22)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers (2016) (22)
- Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient’s management and therapy selection (2013) (22)
- A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer (2017) (22)
- Nuclear Localized LSR: A Novel Regulator of Breast Cancer Behavior and Tumorigenesis (2016) (21)
- Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. (2020) (21)
- ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data (2012) (21)
- Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc (2015) (21)
- "Intrinsic Gene Expression" subtypes correlated with grade and morphometric parameters reveal a high proportion of aggressive basal-like tumors among black women of African ancestry. (2004) (21)
- SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling (2017) (21)
- Genetic determinants of the molecular portraits of epithelial cancers (2019) (20)
- Genetic variation in Transaldolase 1 and risk of squamous cell carcinoma of the head and neck. (2008) (20)
- Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials. (2009) (20)
- Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. (2012) (20)
- Collective Wisdom: Lobular Carcinoma of the Breast. (2016) (19)
- Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. (2010) (19)
- Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy – results from two independent randomized trials (2018) (19)
- Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest? (2015) (19)
- FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. (2018) (19)
- Molecular analysis of TCGA breast cancer histologic types (2021) (19)
- Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer (2022) (19)
- MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression (2019) (19)
- PIK 3 CA and PIK 3 CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor – Positive Breast Cancer (2009) (18)
- CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping (2015) (18)
- Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. (2013) (18)
- Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. (2012) (18)
- PAM 50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer (2012) (17)
- Micro-Scale Genomic DNA Copy Number Aberrations as Another Means of Mutagenesis in Breast Cancer (2012) (17)
- Common genetic variation in GATA-binding protein 3 and differential susceptibility to breast cancer by estrogen receptor alpha tumor status. (2007) (16)
- Virus expression detection reveals RNA-sequencing contamination in TCGA (2020) (16)
- Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer (2019) (16)
- TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases (2018) (16)
- Clustering microarray-derived gene lists through implicit literature relationships (2007) (16)
- Tumor classification using gene expression patterns from DNA microarrays (2000) (16)
- Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells (2021) (16)
- MicroRNA-30 c targets cytoskeleton genes involved in breast cancer cell invasion (2012) (15)
- Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment (2020) (15)
- Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas (2019) (14)
- RB 1 and p 53 at the crossroad of EMT and triple negative breast cancer (2011) (14)
- Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) (2017) (14)
- Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. (2021) (14)
- A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer (2018) (13)
- Genome Medicine in Cancer: What's in a Name? (2015) (13)
- Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer (2016) (13)
- MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements (2011) (13)
- Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer (2020) (13)
- Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation (2017) (13)
- implications Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical (2001) (12)
- Hormone receptor negative and basal-like subtypes are overrepresented in invasive breast carcinoma from women of African ancestry (2005) (12)
- Microarrays and Epidemiology: Ensuring the Impact and Accessibility of Research Findings (2009) (12)
- The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies (2015) (12)
- Palbociclib--Taking Breast-Cancer Cells Out of Gear. (2015) (12)
- Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer (2018) (12)
- Oncogenic Deregulation of EZH 2 as an Opportunity for Targeted Therapy in Lung Cancer (2016) (12)
- A multi-omic single-cell landscape of human gynecologic malignancies. (2021) (12)
- Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer (2021) (11)
- Collective Wisdom: Lobular Carcinoma of the Breast. (2016) (11)
- Visualization of Cross‐Platform Microarray Normalization (2009) (11)
- Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). (2010) (11)
- TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. (2019) (11)
- Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders. (2009) (10)
- Radiation-Induced Gene Signature Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients (2012) (10)
- MultiK: an automated tool to determine optimal cluster numbers in single-cell RNA sequencing data (2021) (10)
- Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression (2019) (10)
- Addendum: Standardizing global gene expression analysis between laboratories and across platforms (2005) (10)
- A retroviral vector for siRNA expression in mammalian cells (2007) (10)
- Borderline estrogen receptor-positive breast cancers in black and white women. (2019) (10)
- Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications (2019) (10)
- Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER. (2015) (10)
- PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients (2017) (10)
- Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab (2018) (9)
- A supervised risk predictor of breast cancer based on biological subtypes (2008) (9)
- Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study (2017) (9)
- Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer (2018) (9)
- Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. (2017) (9)
- A murine preclinical syngeneic transplantation model for breast cancer precision medicine (2017) (8)
- FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 (2021) (8)
- c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression (2015) (8)
- PAM50 and Risk of Recurrence Scores for Interval Breast Cancers (2018) (7)
- JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES. (2019) (7)
- WITHDRAWN: Deconstructing the molecular portraits of breast cancer. (2010) (7)
- Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases (2017) (7)
- Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling (2014) (7)
- A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels (2020) (7)
- Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristics (2021) (7)
- Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors (2015) (7)
- Breast cancer molecular subtypes and locoregional recurrence (2008) (6)
- The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor (2019) (6)
- Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy (2021) (6)
- Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis (2022) (6)
- I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms (2019) (6)
- Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. (2010) (6)
- Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy (2021) (6)
- TU-AB-BRA-08: Radiomics in the Analysis of Breast Cancer Heterogeneity On DCE-MRI (2015) (6)
- Inherited predisposition to breast cancer in the Carolina Breast Cancer Study (2021) (6)
- Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features (2020) (6)
- Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. (2022) (6)
- Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts (2017) (6)
- Kinome reprogramming response to MEK inhibition: A window-of-opportunity trial in triple-negative breast cancer (TNBC). (2013) (6)
- Abstract 3592: Improved indel detection in RNA-seq data via assembly based re-alignment reveals expressed Epidermal Growth Factor Receptor indels in Lung Adenocarcinoma (2017) (6)
- Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. (2019) (6)
- 12OMOLECULAR SUBTYPE OF BREAST CANCER METASTASES SIGNIFICANTLY INFLUENCES PATIENT POST-RELAPSE SURVIVAL (2014) (5)
- Title: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically-important and correspond to different normal cell types (2010) (5)
- Abstract P2-10-01: PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy (2012) (5)
- Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay (2018) (5)
- Receiver operating characteristic curves and confidence bands for support vector machines (2018) (5)
- The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. (2011) (5)
- Abstract S1-05: In-depth genomic analysis of ER+ breast cancers during development of endocrine resistance (2015) (5)
- Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. (2022) (5)
- Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T Cells (2021) (5)
- Department of Pathology, Thom as Jeffe rson University, Identific ation of conserved gene expression features between murine mammary carcinoma models and human breast tumors. (2007) (5)
- Molecular and Cellular Pathobiology Oncogenic PI 3 K Mutations Lead to NFk B – Dependent Cytokine Expression following Growth Factor Deprivation (2012) (5)
- Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance) (2019) (5)
- Genomics, prognosis, and therapeutic interventions (2014) (5)
- 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer (2012) (5)
- Gene-Level Germline Contributions to Clinical Risk of Recurrence Scores in Black and White Patients with Breast Cancer (2021) (4)
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer (2012) (4)
- A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling (2008) (4)
- TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). (2013) (4)
- Abstract P2-09-05: LCCC 1525: A phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (mTNBC) (2019) (4)
- Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. (2016) (4)
- Abstract 1598: LncRNA AK001796 as a therapeutic target in aggressive breast cancers (2016) (4)
- Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2015) (4)
- Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network (2020) (4)
- Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention. (2009) (4)
- Abstract S3-05: Patient-derived xenograft study reveals endocrine therapy resistance of ER+ breast cancer caused by distinct ESR1 gene aberrations (2013) (4)
- Breast cancer intrinsic subtypes by PAM50 in older women. (2012) (4)
- Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (2022) (4)
- Correction: Statistical modeling for selecting housekeeper genes (2008) (4)
- Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast Cancer (2022) (3)
- Abstract PD9-04: FGFR4 as a key regulator of HER2E subtype in the primary and metastatic setting (2019) (3)
- Comparison of Breast CancerMolecular Features and Survival byAfrican and EuropeanAncestry in The Cancer GenomeAtlas (2017) (3)
- Roles of miRNAs in breast cancer stem cells, drug sensitivity, and spontaneous metastases in orthotopic human-in-mouse models. (2011) (3)
- I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms (2018) (3)
- Overview of Gene Expression Profiling and Novel Translational Technologies in Breast Cancer. (2009) (3)
- Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype (2018) (3)
- Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer (2021) (3)
- Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics (2021) (3)
- Hierarchical task-driven feature learning for tumor histology (2015) (3)
- Deep Multi-View Learning via Task-Optimal CCA (2019) (3)
- Identification of conserved gene expression features across human and murine mammary tumors (2006) (3)
- PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers (2012) (3)
- Abstract 3306: Wnt pathway dynamics in breast cancer progression (2016) (3)
- 162PDPathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4) (2017) (3)
- Cancer Therapy : Preclinical Combined PI 3 K / mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models (2012) (3)
- Abstract P6-02-09: Role of HGF in obesity-associated tumorigenesis: C3(1)-Tag mice as a model for human basal-like breast cancer (2012) (3)
- The landscape of immune microenvironments in racially-diverse breast cancer patients. (2022) (3)
- Abstract 3703: A genomic characterization of testicular germ cell tumor immune microenvironment (2017) (3)
- Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes. (2009) (2)
- Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell Lymphoma (2011) (2)
- RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer (2022) (2)
- Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial. (2011) (2)
- Abstract 2547: Discovery and characterization of late-stage breast cancer estrogen receptor alpha 1 bound long non-coding RNAs (2017) (2)
- Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer (2023) (2)
- The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases. (2010) (2)
- Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy – A GEICAM/ 9906 sub-study (2013) (2)
- PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis (2019) (2)
- The other triple-negative breast cancer: Immunohistochemical and clinicopathologic characterization of the Claudin-low subtype. (2011) (2)
- Reply to Y.Yamamoto et al. (2013) (2)
- Gene expression-based predictors of chemotherapy response in basal-like breast cancer. (2012) (2)
- Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution. Commentary (2008) (2)
- Abstract S4-02: A comprehensive analysis of fusion transcripts in breast cancer reveals associations between number of fusion transcripts, copy number events, gene expression profiles, and potentially clinical outcome (2016) (2)
- 120MO Prognostic value of immune gene-expression signatures (iGES) vs tumor-infiltrating lymphocytes (TILs) in early-stage HER2+ breast cancer: A combined analysis of CALGB 40601 (C40601) and PAMELA trials (2021) (2)
- Complete RNA-seq analysis of cancer transcriptomes from FFPE samples (2010) (2)
- Erratum: Diversity of gene expression in adenocarcinoma of the lung (Proceedings of the National Academy of Sciences of the United States of America (2001) 98 (13784-13789)) (2002) (2)
- Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer (2022) (2)
- Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy (2017) (2)
- Association of a compact 13-gene VEGF signature with OS in E2100. (2012) (2)
- Gene signature of cancer stem cells in an intrinsic subgroup of breast cancers with mesenchymal properties (2008) (2)
- Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence (2022) (2)
- Abstract SY12-03: Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. (2013) (2)
- TP 53 protein levels , RNA-based pathway assessment , and race among invasive breast cancer cases (2018) (2)
- P1-06-04: PAM50 Proliferation Index Predicts Response to Weekly Adjuvant Paclitaxel in Node-Positive Operable Breast Cancer. (2011) (2)
- Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention (2005) (2)
- Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. (2021) (2)
- Chemotherapy benefit for 'ER-positive' breast cancer and contamination of Nonluminal subtypes-waiting for TAILORx and RxPONDER. (2015) (2)
- Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2020) (2)
- Prediction of long-term survival using expression of FOXA1, a determinant of estrogen response domains in breast cancer. (2006) (1)
- Abstract 994: Long noncoding RNAs generated from the BRCA1 pseudogene regulate genomic instability and homologous recombination repair (2016) (1)
- Abstract PD8-03: ESR1 gene fusions drive endocrine therapy resistance and metastasis in breast cancer (2018) (1)
- Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. (2009) (1)
- Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study (2022) (1)
- MultiK: an automated tool to determine optimal cluster numbers in single-cell RNA sequencing data (2021) (1)
- Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies (2013) (1)
- Gene expression profiles to predict outcome in breast cancer (2009) (1)
- 4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC) (2020) (1)
- Pairwise Nonlinear Dependence Analysis of Genomic Data (2022) (1)
- Biology of Human Tumors Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Speci fi c Breast and Ovarian Cancer (2014) (1)
- Abstract PD1-03: Multivariate analysis of subtype and gene expression signatures predictive of pathologic complete response (pCR) in triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) (2017) (1)
- Abstract A002: Purity Independent Subtyping of Tumor (PurIST): Real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications (2022) (1)
- Abstract S3-05: Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer (2017) (1)
- TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. (2014) (1)
- Abstract 2649: Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors (2015) (1)
- S6-5: Obesity Drives Epithelial-to-Mesenchymal Transition and Tumor Progression in a Novel Claudin-Low Mammary Cancer Model. (2011) (1)
- Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. (2023) (1)
- α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. (2016) (1)
- Multiclass Distance Weighted Discrimination with Applications to Batch Adjustment (2010) (1)
- development stem cell dedifferentiation during mammary and tumor BRCA 1 suppresses epithelial-to-mesenchymal transition and Updated (2014) (1)
- ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data (2012) (1)
- DNA MICROARRAYS AS "MICROSCOPES" FOR WATCHING A GENOME IN ACTION (1998) (1)
- PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors (2021) (1)
- SFRP2 Stimulates Angiogenesis via a Calcineurin/NFAT Signaling Pathway (2009) (1)
- Rare germline copy number variants (CNVs) and breast cancer risk (2022) (1)
- Mre11 Dysfunction Is Associated With Triple-Negative Breast Cancer and Confers Sensitivity to DNA Damaging Therapy (2016) (1)
- Abstract 266: How many epidemiological types of breast cancer: Two, three, four, or more (2014) (1)
- 794 Allele-specific copy number analysis of breast carcinomas (2010) (1)
- Characterization of aggressive breast cancer in African American and Caucasian women: Patterns of gene expression in primary breast tumors. (2004) (1)
- Abstract P2-06-11: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation (2016) (1)
- Microarray profiling is feasible using archived tissue from a Cooperative Group Clinical Trial: Results from a pilot study in CALGB 9342 (2005) (1)
- Gene-level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients (2021) (1)
- Abstract PL01-03: The therapeutic implications of genome sequencing and expression analyses for breast cancer. (2013) (1)
- p53 mutational status, but not immunohistochemical staining (IHC), is associated with a clinical response of the primary tumor in women receiving neoadjuvant docetaxel-capecitabine chemotherapy for locally advanced breast cancer. (2009) (1)
- Abstract PD6-4: ESR1 gene fusions implicated in endocrine therapy resistance of ER+ breast cancer (2015) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Transcriptome-wide association study of risk of recurrence in Black and White breast cancer patients (2021) (1)
- Gene expression subtype and p53 mutational status are correlated among neoadjuvantly treated breast cancers in UNC LCCC9819 and I-SPY1 (CALGB 150007/ACRIN 6657). (2006) (1)
- 186PBreast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms (2017) (1)
- Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts (2013) (1)
- Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. (2010) (1)
- Abstract LB-87: Analysis of luminal-type breast cancer by massively parallel sequencing (2011) (1)
- Abstract P3-09-08: An automated tool to determine optimal cluster numbers in single-cell RNA sequencing data identifies key prognostic subsets of T cells in breast tumors (2022) (1)
- PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors (2021) (1)
- Short Communication Expression of Cytokeratins 17 and 5 Identifies a Group of Breast Carcinomas with Poor Clinical Outcome (2002) (1)
- Characterization of aggressive breast cancer in African American and Caucasian women: Patterns of gene expression in primary breast tumors (2004) (1)
- Abstract 5024: mDX400, the murine analog against the anti-PD1 antibody MK-347 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer (2014) (1)
- Abstract P4-07-08: Prognostic value of intrinsic subtypes (IS) in hormone receptor-positive (HoR+) metastatic breast cancer (MBC): A systematic review and meta-analysis of prospective trials (2022) (1)
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases (2022) (1)
- BreakTrans: uncovering the genomic architecture of gene fusions (2013) (1)
- FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036 (2021) (1)
- P1-06-13: An Amplicon-Driven Aromatase Inhibitor Response (ADAIR) Signature Provides an Orthogonal Risk Classifier for ER+ Breast Cancer. (2011) (1)
- Abstract P2-16-13: Phase I dose escalation clinical trial of the PI3K inhibitor BKM120 and capecitabine (C) in metastatic breast cancer (MBC) (2013) (1)
- Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. (2023) (1)
- 42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC) (2021) (1)
- Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer (2023) (0)
- Abstract 1176: αB-Crystallin expression across different stages and subtypes of breast cancer analyzed using tissue microarrays (2010) (0)
- 163 A Subtype of Gene Expression with Claudin-low Features in Normal Breast Tissue and in Fibroadenomas (2012) (0)
- Abstract C045: Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biologic features (2020) (0)
- Abstract P1-05-11: Comprehensive comparison of breast cancer molecular portraits by African and European ancestry in the cancer genome atlas (2017) (0)
- Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy–driven Metabolic Reprogramming (2023) (0)
- Abstract PD4-09: PD4-09 Single cell RNA-sequencing identifies intra-tumoral cellular heterogeneity and drug-induced subpopulation shifts in Triple Negative Breast Cancer mouse models (2023) (0)
- Rare copy number variants (CNVs) and breast cancer risk (2021) (0)
- Abstract 832: MicroRNA-30c inhibits human breast tumor chemo-resistance by regulating twinfinlin-1 (TWF1) and IL-11. (2013) (0)
- Development and verification of the PAM50-based Prosigna breast cancer gene signature assay (2015) (0)
- Abstract P6-04-05: Genotype-phenotype classification of triple negative breast cancers (TNBC) in women of African descent using the PAM50 NanoString platform and genomic data (2016) (0)
- Abstract GS2-01: Discovery and characterization of an estrogen bound LncRNA in late-Stage breast cancer (2018) (0)
- Expression subtypes of lung adenocarcinoma and squamous cell carcinoma reveal a varied immune landscape and unique somatic genetic features suggesting differential response to multiple drug targets (2016) (0)
- Mre11 liberates cGAS from nucleosome sequestration during tumorigenesis (2022) (0)
- Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases (2022) (0)
- Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer (2017) (0)
- Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence (2023) (0)
- Abstract A039: The role of long noncoding RNAs in epithelial to mesenchymal transition and cancer stem cells (2013) (0)
- High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer (2022) (0)
- P4-03-03: Therapeutic Sensitivities of Mouse Models of Human Breast Cancer. (2011) (0)
- Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC) (2016) (0)
- Abstract 2285: Germline genetic variation modulates tumor latency and response to therapy in a mouse model of basal-like breast cancer (2015) (0)
- Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer. (2013) (0)
- Abstract 3354: Relationship between tumor-associated macrophages (TAMs), tumor delivery, and efficacy of PEGylated liposomal doxorubicin (PLD) and non-liposomal doxorubicin (NL-doxo) in genetically engineered mouse models (GEMMs) of breast cancer (BC). (2013) (0)
- Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer (2011) (0)
- Abstract P5-05-01: Metabolite profiling and RNA-seq identifies novel metabolomic-genomic biomarker and therapeutic options for rapidly proliferating breast cancers (2022) (0)
- Abstract P1-13-16: Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC) (2023) (0)
- Department of Pathology, Thomas Jefferson University, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (2020) (0)
- Abstract ES7-2: Next Generation Sequencing for the Clinician (2010) (0)
- Predictions of breast cancer local and distant metastasis (2006) (0)
- Abstract P2-09-05: Independent validation of the PAM50-based chemo-endocrine score (CES) in hormonal receptor positive (HR+)/HER2+ breast cancer (BC) treated with neoadjuvant (NA) anti-HER2-based therapy (2018) (0)
- A framework for transcriptome-wide association studies in breast cancer in diverse study populations (2020) (0)
- 272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC) (2022) (0)
- Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect (2012) (0)
- Abstract 200: A transcribed BRCA1 pseudogene regulates gene expression and promotes breast cancer cell proliferation. (2012) (0)
- Clinical Cancer esearch ing , Diagnosis , Prognosis omparison of PAM 50 Intrinsic Subtyping with unohistochemistry and Clinical Prognostic Factors in oxifen-Treated Estrogen Receptor – Positive R ast Cancer (2010) (0)
- Abstract 5334: Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation (2014) (0)
- Abstract 568: Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer (2017) (0)
- Abstract LB-327: Analytical performance of the nCounter analysis system for gene expression cancer signatures (2011) (0)
- DMBA treatment of heterozygous MMTV-Neu and MMTV-Neu/P53 knockout mice: histopathologic characterization, array analysis, and chemopreventive efficacy of rexinoids. (2007) (0)
- Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer (2014) (0)
- Abstract 2307: Targeted agents and chemotherapeutic treatments of genetically engineered Basal-like breast cancer mouse model (2015) (0)
- Abstract P3-07-05: Not presented (2019) (0)
- Abstract B185: Epithelial cancer cell-expressed genes contribute to clinically relevant immune-based classifications of breast cancer (2019) (0)
- Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells (2017) (0)
- Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study (2017) (0)
- Abstract 4044: The immune phenotype in serial biopsies from metastatic TNBC undergoing chemo-immunotherapy (2019) (0)
- Progesterone receptor isoform ratio to define the molecular signature of luminal breast cancers and their antiprogestin responsiveness. (2015) (0)
- Abstract PD9-03: Genomic analysis of the CALGB 40603 (Alliance) neoadjuvant trial in TNBC identifies immune features associated with pathological complete response and event-free survival (2021) (0)
- Gene signature of cancer stem cells is manifested within an intrinsic subgroup of breast cancers with mesenchymal properties (2008) (0)
- RNAseq and DNA whole-exome sequence analysis reveal novel response signatures to IO treatment in muscle invasive bladder cancer (MIBC) patients. (2019) (0)
- Correction: Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression (2019) (0)
- Abstract IA12: Precision medicine for triple-negative breast cancer patients using a systems biology approach (2018) (0)
- Expression profiles can predict both general chemotherapy and gemcitabine-specific responses in breast cancer patients receiving neoadjuvant therapy. (2006) (0)
- A class of GATA3 mutation reprograms the breast cancer transcriptional network through gain and loss of function (2017) (0)
- Reply to L.C. Panasci (2009) (0)
- Bryan Generates Rare Breast Cancer Subtypes Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and (2013) (0)
- Abstract 4496: Cytokine-induced post-translational modifications of FOXA1 affect enhancer selection and estrogen signaling in breast cancer cells (2019) (0)
- Reproducible molecular characterization of non-small cell lung cancer from paraffin. (2013) (0)
- Abstract 822: The molecular diversity of Luminal A breast cancer. (2013) (0)
- Abstract P4-05-01: Genetic analysis of the role of Brca1 in suppression of basal-like breast cancer (2015) (0)
- Abstract LB-103: Conditional loss of ErbB3 delays mammary gland hyperplasias induced by mutant PIK3CA in transgenic mice, but does not affect mammary tumor latency, gene expression or signaling (2012) (0)
- Abstract P4-12-01: Molecular features and survival outcomes of the intrinsic subtypes of breast cancer based on HER2 gene amplification (2013) (0)
- CES: A chemoendocrine PAM50 based index for breast cancer hormone receptor positive intermediate risk of recurrence (2016) (0)
- Validation of Breast Cancer PAM50 Intrinsic Subtypes by Gene Expression Microarray in a Clinical Laboratory (2013) (0)
- Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women (2021) (0)
- Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC (2020) (0)
- Abstract 4801: Integrated genomic analysis of chromosome 11 in squamous tumors (2015) (0)
- Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. (2013) (0)
- Abstract IA29: Proteogenomic and phosphoproteomic analysis of breast cancer (2016) (0)
- Abstract 3004: Specific microRNAs associate with aggressive breast tumor phenotypes in an ethnically diverse patient cohort (2010) (0)
- Gene expression profiles to forecast the outcome in breast cancer (2009) (0)
- PD-1 checkpoint therapy promotes pro-survival phenotype in regulatory T cells in a model of claudin-low breast cancer (2019) (0)
- Prognostic and Predictive Impact of Intrinsic Biological Classification by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results from the NCIC CTG MA.12 Trial. (2009) (0)
- Abstract P5-04-14: Tracking ESR1 mutation clonal evolution in breast cancer usingin situmutation detection (2019) (0)
- 3 Genomic Analysis of Human Tumours for Guiding Therapeutic Selection (2012) (0)
- Abstract S4-01: An integrated genomics approach identifies novel drivers of oncogenic pathway activity in human breast cancer (2013) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Abstract P4-04-02: Characterising the effects of neoadjuvant endocrine therapy on primary cancers and nodal metastasis (2018) (0)
- Abstract 4268: Gene signature of host irradiation from Trp53 null mammary tumors detects radiation-preceded human cancers and has prognostic value for sporadic human breast cancer (2012) (0)
- TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases (2018) (0)
- cancer clinical treatment response in locally advanced breast Gene expression profiles do not consistently predict the (2011) (0)
- Abstract 3332: Obesity drives epithelial/mesenchymal transition and tumor progression in a novel Wnt-1 mammary cancer model (2011) (0)
- Abstract GS2-05: Microscaled proteogenomic methods for precision oncology (2020) (0)
- Therapeutics , Targets , and Chemical Biology Conditional Loss of ErbB 3 Delays Mammary Gland Hyperplasia Induced by Mutant PIK 3 CA without Affecting Mammary Tumor Latency , Gene Expression , or Signaling (2013) (0)
- THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES (2019) (0)
- Virus expression detection reveals RNA-sequencing contamination in TCGA (2020) (0)
- Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome. (2014) (0)
- Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches (2020) (0)
- 140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial (2022) (0)
- Abstract GS1-05: Apobec3 induced mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy by activating B-cells and CD4+ T-cells (2019) (0)
- Comparative genomic analysis of mouse and human mammary tumors (2011) (0)
- Integrating genomics and genetics into clinical trials for patient stratification (2008) (0)
- 629 The molecular portraits of breast cancer and their relationship to mammary stem cells (2010) (0)
- Integrated Metabolic and Gene Expression Profiling Reveals New Therapeutic Modalities for Rapidly Proliferating Breast Cancers (2021) (0)
- Abstract PS18-12: Comparative analysis of differential gene expression by ancestry using primary breast cancers from Nigeria and the cancer genome atlas (TCGA) (2021) (0)
- Abstract P5-03-05: Genomic analysis and efficacy of entinostat in basal-like and HER2-overexpressing models (2016) (0)
- Abstract 5240: Functional and therapeutic significance ofESR1gene fusions in breast cancer (2018) (0)
- AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome. (2011) (0)
- Abstract PD1-2: Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603 (2015) (0)
- Abstract PO-055: Molecular characterization of papillary thyroid cancer in relation to ionizing radiation dose following the Chernobyl accident (2021) (0)
- Altered NDRG1 expression in breast cell lines influences apoptosis (2008) (0)
- S2-6: ErbB3 Expression Is Required for Maintenance of Normal and Transformed Luminal Breast Epithelial Cells. (2011) (0)
- Abstract P1-01-08: DPYSL3 modulates proliferation and migration in claudin-low breast cancer (2018) (0)
- Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+breast cancer as a mechanism of HER2 resistance (2013) (0)
- Molecular and Cellular Pathobiology Cancer Research Fibroblast Growth Factor Receptor Signaling Dramatically Accelerates Tumorigenesis and Enhances Oncoprotein Translation in the Mouse Mammary Tumor Virus – Wnt-1 Mouse Model of Breast Cancer (2010) (0)
- 339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer (2021) (0)
- Abstract P4-05-06: Host inflammation and breast cancer molecular subtypes: Updated results from a TCGA sub-analysis (2013) (0)
- Abstract LB-149: A novel strategy to inhibit CpG island hypermethylation and restore BRCA1 expression (2015) (0)
- TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study (2021) (0)
- Abstract P5-19-01: Targeting the HER3-phosphatidyl inositol-3 kinase pathway in breast cancers (2012) (0)
- The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours (2019) (0)
- HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial (2022) (0)
- Abstract B54: Single-cell analytics in claudin-low TNBC reveals immunostimulatory effects of low-dose metronomic cyclophosphamide treatment (2020) (0)
- Chemotherapy coupled to macrophage inhibition leads to enhanced T and B cell infiltration and durable triple negative breast cancer regression (2021) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Abstract LB-292: Race-associated gene expression in tumors and breast cancer mortality disparities (2014) (0)
- Genetic causes of resistance to entinostat in luminal breast cancer model systems. (2017) (0)
- Inherited predisposition to breast cancer in the Carolina Breast Cancer Study (2021) (0)
- NanoString Technologies Announces Eleven Prosigna/PAM50 Presentations at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium (0)
- Ki-67 is a Luminal B marker that identifies a high-risk subgroup in hormone receptor positive and node negative breast cancer (2007) (0)
- Abstract PS4-12: Potential value of FOXA1 expression as genomic predictor of response to docetaxel and carboplatin neoadjuvant (NA) chemotherapy in patients with triple negative breast cancer (TNBC) (2021) (0)
- Abstract P3-08-04: Transient state change, but not permanent subtype change, after HER2-targeted therapy for HER2-positive breast cancer (2019) (0)
- SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling (2017) (0)
- Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry (2023) (0)
- GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network (2018) (0)
- Abstract P6-08-01: Race and recurrence by PAM50 intrinsic subtype and ROR-PT score: The Carolina breast cancer study (2018) (0)
- Abstract P6-05-02: Intrinsic subtype and gene expression changes between primary and metastatic breast cancer (2016) (0)
- Resource Reveals Molecular Classification Multiplatform Analysis of 12 Cancer Types within and across Tissues of Origin (0)
- Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity. (2023) (0)
- Frequency of breast cancer subtypes among African American women in the AMBER consortium (2018) (0)
- Abstract PD8-01: Race and age differences in PAM50 biomarker status in the Carolina breast cancer study (2017) (0)
- Abstract P4-02-30: Association between tumor infiltrating lymphocytes (TILs) and the HER2DX assay in early-stage of HER2-positive (HER2+) breast cancer (2023) (0)
- Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential (2015) (0)
- Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas (2019) (0)
- PD03-06: Basal-Like Breast Tumors Are Associated with Frequent Micro Genomic Aberrations in Important Cancer Genes. (2011) (0)
- Impact of tumor and epithelial phenotypes on metabolism in breast cancer (2013) (0)
- Paraffin-based molecular diagnosis of lung cancer reproduces morphologic and molecular subtypes of lung cancer (2016) (0)
- Reply to R.S. Mehta et al (2009) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Abstract PD6-9: Molecular signatures of DCIS to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study (2020) (0)
- Abstract B18: ADSL controls pyrimidine metabolism and triple-negative breast tumorigenesis (2018) (0)
- Abstract P6-07-10: Luminal A vs. Basal-like Breast Cancer: time dependent changes in the risk of relapse in the absence of treatment (2012) (0)
- Abstract P4-05-10: PIK3CA mutations are enriched in invasive lobular carcinomas and invasive mammary carcinomas with lobular features: Results from a TCGA sub-analysis (2013) (0)
- Abstract P5-14-02: Identifying oncogenic enhancer elements in TNBC of the Basal-like subtype using single-cell ATAC-seq and RNA-seq (2023) (0)
- Abstract P3-06-17: Unlocking the transcriptomic potential of formalin-fixed paraffin embedded breast cancer tissues for high-throughput genomic analysis (2019) (0)
- Abstract P2-12-01: A comprehensive assessment of researcher needs to increase biospecimen donations for breast cancer research: A Patients and Researchers Together (PART) Program (2023) (0)
- Abstract LB176: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network identifies microenvironment features as drivers of metastasis (2022) (0)
- Dissection of cooperating genetic pathways involved in aggressive early onset breast cancer reveals mutually distinct roles for BRCA1 and HER2/neu genes (2001) (0)
- Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies (2021) (0)
- Use of a Novel Embryonic Mammary Stem Cell Gene Signature to Improve Human Breast Cancer Diagnostics and Therapeutic Decision Making (2013) (0)
- Abstract P4-08-01: Tumor suppressor PLK2 may serve as a biomarker in triple negative breast cancer for combinational therapy of PLK1 inhibitors with the standard-of-care chemotherapy (2020) (0)
- Abstract 2627: Molecular analyses of histopathologic morphologic features in breast cancer (2016) (0)
- Abstract 3223: Overcome LKB1 mutated cancer resistance to anti-PD1 treatment (2019) (0)
- Abstract 4212: p53 null spindloid murine mammary tumors show features associated with human claudin-low tumors and enrichment for cancer stem cells (2010) (0)
- 2 The Biology of Breast Cancer – The New Super Highway to the Clinic (2012) (0)
- Clinical Cancer esearch ing , Diagnosis , Prognosis g Squamous Cell Carcinoma mRNA Expression Subtypes Reproducible , Clinically Important , and Correspond R ormal Cell Types (2010) (0)
- Abstract P6-03-01: Molecular Dissection of Breast Luminal Cell Transcription Factor Networks (2012) (0)
- TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). (2017) (0)
- Evaluation of a lung cancer RNA expression subtyping panel and comparison with histologic diagnosis in lung tumor samples from multiple data sets including The Cancer Genome Atlas (TCGA). (2014) (0)
- MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression (2019) (0)
- Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer (2018) (0)
- Genes nano-46 et procedes de prediction de l'evolution du cancer du sein (2013) (0)
- Molecular and Cellular Pathobiology Gene Pro fi ling of Canine B-Cell LymphomaReveals Germinal Center and Postgerminal Center Subtypes with Different Survival Times , Modeling Human DLBCL (2013) (0)
- Abstract P3-15-01: Patients and Researchers Together (PART); a patient-centered tumor tissue collection PARTnership between patients and researchers to increase tissue donations for breast cancer research (2022) (0)
- Abstract S6-1: Exploration of isoform switching and mutation expression in breast cancer by mRNA-sequencing analysis (2012) (0)
- 25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial (2022) (0)
- P53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer (2006) (0)
- Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer (2019) (0)
- Supplementary Tables 1–5 and Figures Legend (2008) (0)
- Abstract A027: Endothelial-like properties of triple-negative claudin-low breast cancer cells promote tumor-vascular interactions and tumor permeability (2013) (0)
- Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis (2013) (0)
- Comparative genomic analysis of mouse and human mammary tumors (2011) (0)
- Abstract 993: Identification of estrogen receptor alpha 1 bound lncRNAs in aggressive breast cancer (2016) (0)
- A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance). (2018) (0)
- Paring Neural Networks and Linear Discriminant Functions for Glaucoma (2005) (0)
- Abstract CT026: The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial (2022) (0)
- Abstract P1-04-05: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant paclitaxel, trastuzumab and pertuzumab (THP): a correlative analysis from the DAPHNe phase II clinical trial (2023) (0)
- Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro (2013) (0)
- Abstract A24: Characterization of a novel p53; BRCA1-deficient claudin-low mammary tumor cell line (2016) (0)
- Abstract P1-07-16: Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients (2017) (0)
- Abstract PD18-04: Prognostic implications of PIK3CA mutation by hormone receptor status and intrinsic subtype in early stage HER2-positive breast cancer: a correlative analysis from CALGB 40601 (2023) (0)
- Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer (2017) (0)
- Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC). (2020) (0)
- Abstract S4-01: Identification of early versus late drivers of breast tumors and metastasis (2016) (0)
- OP-JNCI200057 329..337 (2021) (0)
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (0)
- Integrated Metabolic Profiling and Gene Expression Analysis Reveals Therapeutic Modalities in Breast Cancer (2020) (0)
- 153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC) (2022) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- Abstract 5337: MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. (2013) (0)
- Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction (2023) (0)
- Abstract OT-09-08: Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer (2021) (0)
- Abstract PD2-03: Recurrent functionally diverse in-frameESR1gene fusions drive endocrine resistance in breast cancer (2017) (0)
- Abstract A30: Kinome dynamics in triple negative breast cancer in response to chemotherapy (2017) (0)
- Systems Biology and Genomics of Breast Cancer service (2010) (0)
- Abstract 2139: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation (2015) (0)
- Abstract P4-05-15: Breast cancers with BRCA1 and BRCA2 mutations are associated with specific pathologic features and molecular profiles: Results from a TCGA sub-analysis (2013) (0)
- Abstract P5-08-01: DPYSL3 modulates mitosis, migration and epithelial to mesenchymal transition in claudin-low breast cancer (2019) (0)
- Abstract PD4-08: PD4-08 A Novel Single Cell Model of Tamoxifen Response in Primary Human Breast Tumors (2023) (0)
- Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study (2022) (0)
- Abstract P6-01-46: Independent validation of the HER2DX genomic test in HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab +/- pertuzumab (TCH/TCHP): a correlative analysis from a multicenter academic study (2023) (0)
- Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay (2018) (0)
- Abstract 360: Thousands of published cancer signatures and pathways can be collapsed into a handful of non-redundant gene programs: a TCGA pan-cancer analysis (2014) (0)
- Abstract 3331: MicroRNAs regulate breast cancer stem cells and spontaneous metastases in orthotopic xenograft models (2012) (0)
- MS1-3: Tumor Heterogeneity and Metastasis. (2011) (0)
- Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors (2023) (0)
- Abstract 5418: GATA3 zinc-finger mutation induces transcriptional reprogramming in breast cancer through gain and loss of function (2018) (0)
- Abstract 5904:TP53mutation and 5q deletion define common phenotypic changes regardless of tissue of origin (2020) (0)
- Additional file 1: Table S1. of Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy (2015) (0)
- Abstract 4563: Profiling the tumor immune microenvironment of adenocarcinoma and squamous cell NSCLC (2019) (0)
- Abstract P5-04-27: Investigating the incidence of ESR1 gene amplification in breast cancers resistant to multiple endocrine agents (2019) (0)
- Abstract P3-07-04: Intrinsic subtype and therapeutic response among early stage HER2-positive breast tumors from the North Central cancer treatment group (Alliance) N9831 trial (2016) (0)
- Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations. (2018) (0)
- HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. (2022) (0)
- Functional characterization of the novel breast tumor endothelial marker, SFRP2, on angiogenesis in the chick choriallantoic membrane and in vitro (2008) (0)
- Expression profiles can predict specific responses of capecitabine/docetaxel (C/D) based primary systemic therapy in breast cancer (BC) patients receiving neoadjuvant therapy (2007) (0)
- Abstract PD1-08: PAM50 and 21-gene recurrence scores in younger and Black women with breast cancer (2023) (0)
- Immune cell activation among lung adenocarcinoma and squamous cell carcinoma intrinsic subtypes and CD274 (PD-L1) expression. (2016) (0)
- Identification of mRNA isoform switching in breast cancer (2016) (0)
- Abstract P6-04-03: In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer (2020) (0)
- Abstract ES10-2: Understanding breast cancer using a developmental perspective (2020) (0)
- Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series (2019) (0)
- Separation of breast cancer and organ microenvironment transcriptomes in metastases (2019) (0)
- Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. (2018) (0)
- A Bayesian Hierarchical Model for Adaptive Biomarker Strategies in Randomized Phase II Studies (2013) (0)
- HNSCC Gene Expression Subtypes, Including a HPV Subtype, Demonstrate Differential Immune Cell and Biomarker Associations (2018) (0)
- Challenges and Gaps in Clinical Trial Genomic Data Management. (2022) (0)
- Abstract A053: ErbB3 downregulation enhances luminal breast tumor response to antiestrogens (2013) (0)
- Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells (2015) (0)
- Microscaled proteogenomic methods for precision oncology (2020) (0)
- Breast cancer radiosensitization by Lapatinib (2008) (0)
- Abstract A037: Differences in BRCAness/PARP inhibitor response signatures and homologous recombination gene expression across lung adenocarcinoma and squamous cell carcinoma gene expression subtypes (2018) (0)
- Abstract PD9-06: Histopathological and molecular immune landscape and DNA damage response signatures to predict response to carboplatin and docetaxel in TNT trial TNBC cohort (2023) (0)
- Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer (2017) (0)
- 258 Scientific correlatives from LCCC 1525: a phase II study of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer (2020) (0)
- Abstract PD15-10: Identification of BBOX1 as a therapeutic target in triple-negative breast cancer (2021) (0)
- Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study (2017) (0)
- Abstract 4055: Genomic and immune characterization of triple-negative breast cancer brain metastases (2018) (0)
- Abstract 2164: Lung adenocarcinoma subtypes have unique gene mutations (EGFR, TP53), DNA copy number alterations (3q26, 16p13), and patient smoking histories (2010) (0)
- Predictive gene profiles for breast cancer patients (2008) (0)
- Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. (2022) (0)
- Abstract P4-06-02: Multi-parameter FACS sorting identifies higher mutational burden in aromatase inhibitor resistant subclones in estrogen positive breast cancer at diagnosis (2020) (0)
- Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers (2018) (0)
- Abstract PD17-07: Cell-Cycle Inhibition and Immune Microenvironment in HR+/HER2- Breast Cancer During and After preoperative ribociclib and letrozole vesus chemotherapy: A correlative analysis of the 1402-SOLTI/CORALLEEN phase 2 trial (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Charles M. Perou?
Charles M. Perou is affiliated with the following schools:
- Harvard University
- University of Utah
- Institute of Cancer Research
- MD Anderson Cancer Center
- University of California, San Diego
- University of Chicago
- University of Ibadan
- University of California, San Francisco
- Duke University
- Washington University in St. Louis
- McGill University
- Complutense University of Madrid
- University of British Columbia
- Vanderbilt University
- University of Edinburgh
- Stanford University
- University of North Carolina at Chapel Hill
